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Abstract
Background: The biological characteristics of BoHV-4 make it a good candidate as a gene delivery
vector for vaccination purposes. These characteristics include little or no pathogenicity, unlikely
oncogenicity, the capability to accommodate large amounts of foreign genetic material, the ability
to infect several cell types from different animal species, and the ability to maintain transgene
expression in both undifferentiated and differentiated cells.
Results: A recombinant bovine herpesvirus 4 (BoHV-4CMV-IgKE2-14∆TK) expressing an
enhanced secreted form of the bovine viral diarrhea virus (BVDV) structural glycoprotein E2 (gE2-
14), obtained by the removal of the putative transmembrane domain and addition of a 14 amino
acids peptide at its carboxyl terminal and an immunoglobulin K signal peptide to the amino terminal,
was successfully constructed using a Recombineering (recombination -mediated genetic
engineering) approach on BoHV-4 cloned as bacterial artificial chromosome. The galactokinase –
based recombineering system was modified by the introduction of a kanamycin expression cassette
and a kanamycin selection step that allowed a significant reduction of the untargeted background
clones. BoHV-4CMV-IgKE2-14∆TK infected cell lines highly expressed gE2-14, which maintained
native antigenic properties in a serum neutralization inhibition test. When rabbits and sheep were
immunized with BoHV-4CMV-IgKE2-14∆TK, high levels of serum neutralized antibodies against
BVDV were generated.
Conclusion: This work highlights the engineerization of BoHV-4 genome as a vector for vaccine
purposes and may provide the basis for BVDV vaccination exploiting the BoHV-4- based vector
that delivers an improved secreted version of the BVDV structural glycoprotein E2.
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Bovine herpesvirus 4 (BoHV-4) has been isolated from a
variety of samples and cells from healthy cattle and from
cattle that have experienced abortion or affected by metri-
tis, pneumonia, diarrhoea, respiratory infection, and
mammary pustular dermatitis [1]. The virus was first iso-
lated in Europe from cattle with respiratory and ocular
diseases by Bartha et al. [2] and later in the United States
by Mohanty et al. [3]. Subsequently, distinct BoHV-4 iso-
lates were obtained both in Europe and in the United
States [1,4-6]. However, the pathogenic role of BoHV-4
remains unclear and despite its tropism for bovine
endometrial cells [7], experimental disease has been
reproduced by only a limited number of investigators [8].
BoHV-4 is classified as a gammaherpesvirus based on
genome sequence and differs from other Gammaherpesviri-
dae members in important biological properties [9-11].
Unlike most other gammaherpesviruses, BoHV-4 causes a
cytopathiceffect (CPE) and replicates in a variety of pri-
mary cultures and cell lines of bovine and various other
animal species [12]. In addition, there is no evidence for
oncogenicity or growthtransformation by BoHV-4.
In contrast to BoHV-4, bovine viral diarrhoea virus
(BVDV) is a pestivirus considered to be one of the major
viral pathogens of cattle and causes significant economic
losses worldwide [13]. Pestiviruses are classified as a sep-
arate genus within the family Flaviviridae, which also
includes flaviviruses and the hepatitis C virus group [14].
Currently three pestivirus species are recognized, namely,
BVDV, classical swine fever virus, and border disease virus
of sheep. The Pestivirus genomes are positive-stranded
RNAs, usually of approximately 12,300 nucleotides,
which encode polyproteins of around 4,000 amino acids
[15]. Entire or partial genomic sequences of numerous
BVDV, classical swine fever virus, and border disease virus
isolates have been determined [16,17], and their compar-
ison has demonstrated a high degree of sequence conser-
vation among Pestiviruses. The virions of Pestiviruses
consist, together with the RNA, of four structural proteins,
the nucleocapsid C protein and the envelope glycopro-
teins Erns, E1, and E2 [18]. Currently, 11 pestiviral pro-
teins have been identified as products of polyprotein
processing, which occurs co- and post-translationally, due
to the activity of viral and host cell proteases. In the hypo-
thetical polyprotein, the proteins are arranged in the order
Npro/C/Erns/E1/E2/NS2/NS3/NS4A/NS4B/NS5A/NS5B
[19]. The gE2 protein of the BVDV NADL strain consists of
about 370 amino acids and has a calculated molecular
mass of 41 kDa. The N terminus of BVDV gE2 is formed
by Arg-690, and the C terminusis located around amino
acid 1063. The C terminus of gE2 includesapproximately
30 amino acids, which could function as a transmem-
braneanchor for gE2, and has a translocation signal for the
downstreamprotein. Full-length gE2 remains cell associ-
ated in virus-infectedcells [20]. Due to the immunodomi-
nant characteristics of BVDV E2 glycoprotein [19], in the
present work we explored the feasibility of employing a
BoHV-4 – based vector to deliver the BVDV glycoprotein
E2 as a secreted form and generated a model for BVDV
and other pestiviruses vaccination by BoHV-4 expressing
BVDV gE2.
Results
Rational design and construction of a plasmid vector 
expressing BVDV gE2
We first optimized a suitable expression cassette to
achieve a robust expression of gE2 by eukaryotic cells
before attempting to express BVDV gE2 in a BoHV-4 based
vector. It has been reported that mice and cattle immu-
nized with plasmid encoding a secreted form of gE2 devel-
oped significantly higher IgG and virus neutralizing
antibody titres compared to animals vaccinated with plas-
mid encoding a membrane linked gE2 [21]. Two expres-
sion cassettes were therefore constructed, pCMV-IgKE2-14
and pCMV-IgKE2-23, expressing the secreted form of gE2.
pCMV-IgKE2-14 (Fig. 1a), contained the cytomegalovirus
(CMV) promoter, an immunoglobulin K light chain (Igk)
leader sequence specifying secretion of heterologous pro-
teins, the gE2 ORF lacking the putative transmembrane
domain and a polar hydrophilic (as calculated by Hopp &
Woods method (Hopp & Woods 1983)) non structured
14-amino-acid peptide (Fig. 1a and 1c), that we hypothe-
sized would increase the secretion of the protein. To test
this hypothesis, a second expression cassette, pCMV-
IgKE2-23, was constructed as a control. The polar
hydrophilic 14-amino-acid peptide of pCMV-IgKE2-14
was substituted with a less hydrophilic 23-amino-acid
peptide (Fig. 1b and 1d). Next, the translation and secre-
tion of E2 in the culture medium, compared with the frac-
tion retained in the cells, was assessed in transiently
transfected HEK 293T cells, by Western blotting. As shown
in Fig. 1e, gE2-14 was better secreted into the culture
supernatant, compared to gE2-23 that was abundantly
retained in the cell fraction. The densitometric quantifica-
tion of the bands revealed ~10 fold better secretion of E2-
14 compared to E2-23. CMV-IgKE2-14 was then
employed to generate a recombinant BoHV-4.
Site specific targeted integration of IgKE2-14 expression 
cassette into the BoHV-4 based vector genome by GalK 
system
The thymidine kinase (TK) gene has been disrupted in
several herpesviruses, including BoHV-4, by the insertion
of foreign sequences without interfering with viral replica-
tion in vitro [22-25]. Furthermore, this genomic region is
highly conserved among BoHV-4 isolates [25,26], ensur-
ing the stability of the genomic locus for the insertion of
foreign expression cassettes. Therefore, the BoHV-4 TK
gene was chosen as a target site for the insertion of CMV-Page 2 of 12
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Structure and evaluation of plasmid vectors expressing the secreted forms of gE2Figure 1
Structure and evaluation of plasmid vectors expressing the secreted forms of gE2. a) Diagram (not to scale) show-
ing the pCMV-IgKE2-14 vector along with the sequence, and predicted amino-acid product, containing: the CMV enhancer pro-
moter (CMV, in black box), the IgK signal peptide (red box) in frame with the E2 ORF and 14 hydrophilic extra amino acids 
peptide (14aa, green box) and the bovine growth hormone polyadenylation signal (PA, white box). b) Diagram (not to scale) 
showing the pCMV-IgKE2-23 vector along with the sequence and the predicted amino-acid product, containing: the CMV 
enhancer promoter (black box), the IgK signal peptide (red box) in frame with the E2 ORF and 23 hydrophobic extra amino 
acids peptide (23aa, green box) and the bovine growth hormone polyadenylation signal (PA, white box). c) Hydrophilicity plot 
of the 14 aa and 23 aa (in d) peptides with the calculated net charge, iso-electric point and the average hydrophilicity. e) West-
ern immunoblotting of cell extracts and supernatant of cells transfected with pIgKE2-14 and pIgKE2-23.
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expression cassette into the BoHV-4 genome, cloned as
BAC [27]. The BACrecombineering system approach [28],
modified by the introduction of a kanamycin selection
step, was used for this purpose. Accordingly, the galactoki-
nase cassette (GalK) along with a kanamycin resistance
cassette, both under the control of constitutively active
prokaryotic promoters, were subcloned in pINT2 [25] to
be flanked by the BoHV-4 TK gene and adjacent
sequences. The generated targeting vector (TK-KanaGalK-
TK) (Fig. 2a) was excised out from the plasmid backbone
and used for heat-inducible homologous recombination
in SW102 E. Coli containing the BAC BoHV-4 genome.
Following a positive selection in minimal medium con-
taining galactose (on solid agar plate) and a second posi-
tive selection with medium containing kanamycin (liquid
medium), all the clones analyzed displayed the correct
targeting (Fig. 2b). Thus, the second selection with kan-
amycin reduced the background to zero. A second target-
ing vector was generated sub-cloning in pINT2 the CMV-
IgKE2-14 (TK-CMV-IgKE2-14-TK) and re-targeting was
performed to replace the KanaGalK cassette with the
CMV-IgKE2-14 cassette (Fig. 2c). Negative selection on
DOG minimal plates, following a negative selection with
medium containing kanamycin and keeping clones sur-
viving in medium containing chloramphenicol but dieing
in medium containing kanamycin, allowed the isolation
of clones all positive for the right targeting, without back-
ground (Fig. 2c and 2d). Next, the BAC BoHV-4 genome
transporting the CMV-IgKE2-14 cassette into the TK locus
was transfected in BEK cells expressing the Cre recombi-
nase to remove the BAC cassette flanked by the lox
sequences and to reconstitute the infectious virus (BoHV-
4CMV-IgKE2-14∆TK).
BoHV-4CMV-IgKE2-14∆TK allows robust expression and 
secretion of gE2-14 in the supernatant of infected cells
To evaluate gE2-14 expression by the BoHV-4CMV-IgKE2-
14∆TK infection, several bovine cell lines, including BEK,
stromal, BEND, PEB, MDBK and BoMac cells were acutely
infected with 5 m.o.i. of BoHV-4CMV-IgKE2-14∆TK; at 6
h post-infection, the medium was removed, cells were
gently washed with serum-free medium to eliminate any
trace of serum protein and incubatedfor 72 h with new
serum-free medium. Thus, the only proteins present in the
medium were cell-secreted proteins. The medium was
analyzed by Western immunoblotting. As shown in Fig.
3a, of gE2-14 expression well detected for all cell lines
tested, although high variability was observed among the
lines. The highest expression was observed for the stromal
cell line, while the MDBK cell line gave the lowest.
The outcome of BoHV-4 infection depended on the cell
type: ì) persistent infection, as is the case for BoMac cells
where, following permissive infection with an extensive
CPE, surviving and replicating cells were found to be per-
sistently infected, maintaining the viral genome over
many passages and producing low levels of infectious
virus. ìì) permissive infection, characterized by strong CPE
and an abundant viral replication and high level of infec-
tious virus production, as observed in BEK cells. ììì) un-
permissive infection, observed in the rhabdomyosarcoma
cell line (RD-4), where BoHV-4 infected cells produced
low levels of early and late viral RNAs, but caused no cyto-
pathic effect.
gE2-14 expression and secretion was assessed for these
three types of infection and a time course was performed,
sampling the medium at 24, 48 and 72 h post infection.
The best expression was observed for persistently infected
BoMac cells (Fig. 3b).
gE2-14 retains native antigenic properties
The E2 protein plays a major role in virus attachment and
entry of BVDV [29]. Furthermore, BVDV E2 is important
for the inductionof neutralizing antibodies [15] and pro-
tection against BVDV challenge in cattle [30,31]. There-
fore, we explored the antigenic properties of gE2-14
expressed and secreted by BoHV-4CMV-IgKE2-14∆TK
infected cells, by performing a serum neutralization inhi-
bition test, based on the capability of gE2-14 to reduce or
block the activity of neutralizing antibodies against BVDV
(Fig. 4a). Four heat-inactivated bovine sera that were pos-
itive for virus-neutralizingantibodies against BVDV were
selected and incubated with conditioned medium con-
taining gE2-14. Positive and negative controls, as well as
virus controls, were included (Fig.4b). Virus suspension
containing BVDV NADL was added to each well. After
incubation, MDBK cell suspension was added. Viral infec-
tivity and serum-neutralizing activitythrough the cyto-
pathic effect were detected by microscopy and/or crystal
violet staining of the cell monolayer. The neutralization
antibody titers were expressed as the reciprocal of the final
dilution of serum that completely inhibited viral infectiv-
ity. A strong reduction of the neutralizing activity of the
sera was obtained by the conditioned medium containing
gE2-14 (Fig. 4b and 4c). No neutralizing inhibition was
observed in the control assay performed with conditioned
medium in the absence of gE2-14. These findings allowed
us to show that gE2-14 maintains the native antigenic
properties of BVDV E2.
BoHV-4CMV-IgKE2-14∆TK expressing gE2-14 is 
immunogenic and elicits the production of neutralizing 
antibodies against BVDV
After collection of preimmune serum, a group of 3 BVDV
serum negative rabbits and a group of 4 BVDV serum neg-
ative sheep were intravenouslyinoculated with BoHV-
4CMV-IgKE2-14∆TK. An identical inoculation was per-
formed 2 weeks later. Blood samples were collectedPage 4 of 12
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Overall strategy of BoHV-4CMV-IgKE2-14∆TK generationFigure 2
Overall strategy of BoHV-4CMV-IgKE2-14∆TK generation. a) First targeting, where kanamycin resistant cassette 
(Kana) adjacent to the galactokinase cassette (GalK) and flanked by BoHV-4 thymidine Kinase gene and adjacent sequences 
(TK), are introduced into the TK gene of BoHV-4 genome cloned as bacterial artificial chromosome (BAC-BoHV-4) via heat 
inducible homologous recombination in SW 102 E. coli. Following a positive selection on (solid) minimal plates containing galac-
tose as the only source of carbon and a positive selection on (liquid) medium containing Kanamycin. Selected clones, ferment-
ing lactose (red colonies) on McConkey plates (representative plate). b) HindIII restriction enzyme analysis of 6 clones out of 
hundreds, all displaying the right targeting, where a new 2.6 kb band (indicated by arrow, 1 to 6) corresponding to the insertion 
of the Kana/GalK cassettes is present but missing in the untargeted control. c) Second targeting and counter selection, where 
the Kana/GalK cassettes were removed via heat inducible homologous recombination and replaced with CMV-IgKE2-14 
expression cassette. All colonies tested through HindIII restriction enzyme analysis and agar gel electrophoresis (d) shows the 
right re-targeting. The disappearing of the 2.6 kb band and the appearing of a new band with a lower molecular size are indi-
cated by arrows.
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antibodies. Furthermore, body temperature and develop-
ment of clinical signs were monitored daily. None of the
animals developed fever or other clinical signs during the
time of observation (5 weeks). Both groups of animals
developed an antibody response against BVDV, detectable
the second week after the first viral inoculation and reach-
ing the plateau phase at the fourth week post-viral inocu-
lation (Fig.5a and 5b). Antibodies were observable 2
weeks following the first viral inoculation and the blood
samples were collected before the second viral inocula-
tion. It is therefore possible to conclude that a single inoc-
ulation of BoHV-4CMV-IgKE2-14∆TK was able to elicit a
Inhibition of serum neutralization (SN) test, to assay the gE2-14 an genic properti s expressed and s cre ed by BoHV-4CMV-IgKE2-14∆TK inf cted c llsFigure 4
Inhibition of serum neutralization (SN) test, to assay 
the gE2-14 antigenic properties expressed and 
secreted by BoHV-4CMV-IgKE2-14∆TK infected 
cells. (a) Diagram showing the principle of the assay, where 
BVDV neutralizing antibodies pre-incubated with medium 
containing gE2-14 are blocked, allowing the virus to infect 
and destroy the cell monolayer. (b) The quantitative assay 
performed in a 96-multiwell plate where 4 sera (1, 2, 3, and 
4) containing neutralizing antibody against BVDV were tested 
at different dilutions in the presence of gE2-14 (+Sera +E2) 
and in the absence of gE2-14 (+Sera -E2). Control virus was 
established in the absence of sera and presence of gE2-14 and 
in the absence of sera and gE2-14. Crystal violet staining 
allows macroscopic evaluation of the integrity or the 
destruction of the cell monolayer. (c) Bar graph showing the 
quantification of serum neutralization made on the basis of 
three different experiments (** = P < 0.001). Results are 
expressed as the log2 of the highest dilution of the serum 
that inhibited the development of virus-induced cytopathic 
effect in cell culture.
Expression analysis of BoHV-4CMV-IgKE2-14∆TK infected cell linesFigur  3
Expression analysis of BoHV-4CMV-IgKE2-14∆TK 
infected cell lines. a) Western immunoblotting of superna-
tant coming from several bovine cell lines infected with 
BoHV-4CMV-IgKE2-14∆TK. b) Time course of gE2 expres-
sion of cells sustaining different types of infection (persistent, 
permissive and unpermissive infection).Page 6 of 12
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of animals as demonstrated by serum neutralization test
(Fig. 5a and 5b).
Discussion and conclusion
In the present study, the establishment and employment
of a recombinant BoHV-4, expressing a secreted form of
BVDV gE2, has been described. The gE2 protein plays a
major role in virus attachment and entry of BVDV [29].
Furthermore, BVDV gE2 is important for the induction of
neutralizing antibodies and protection against BVDV
challenge in cattle [20,30,31]. In vitro analysis demon-
strated that deletion of the transmembrane anchor and
addition of a heterologous signal sequence resulted in
efficient secretion of gE2 into the culture medium. In con-
trast, full-length gE2, as well as truncated gE2 without sig-
nal sequence, remained entirely cell-associated. Animals
immunized with plasmid encoding a secreted form of gE2
developed significantly higher IgG and virus neutralizing
antibody titres compared to animals vaccinated with plas-
mid encoding a membrane linked gE2 [21]. Starting with
this data, we successfully engineerized a eukaryotic
expression cassette secreting high levels of gE2 into the
medium of transfected cells, where the addition of a 14 aa
non-structured, highly hydrophilic peptide to the C-ter-
minus, significantly increased gE2 secretion compared to
a less hydrophilic 23 aa control peptide. Although this 14
aa peptide was added to increase gE2 secretion, it could be
also exploited as a marker to distinguish naturally-
infected from vaccinated animals The next step was to vec-
torialized the expression cassette into a BoHV-4-based
vector clone as BAC. For this purpose, we applied a
Recombineering system (recombination -mediated
genetic engineering) [32], using three λRed-encoded
genes: exo, bet and gam. exo encodes a 5'-3' exonuclease
that produces 3' overhangs from introduced double-
stranded DNA targeting cassettes (dsDNA). bet encodes a
pairing protein that binds to the 3' overhangs and medi-
ates its annealing and homologous recombination with
complementary DNA present on the BAC. At the same
time, gam encodes an inhibitor of the E. coli RecBCD exo-
nuclease and thereby protects the linear DNA-targeting
cassette from degradation by RecBCD. λRed (or the corre-
sponding RecE and RecT genes of the prophage Rac) can
be expressed from a multicopy plasmid using an induci-
ble promoter [33,34]. Alternatively, these genes can be
expressed from a stably integrated defective prophage,
where exo, bet and gam are controlled by the strong phage
promoter pL, under stringent control of the temperature-
sensitive repressor, cI857[35,36]. In the prophage system,
exo, bet and gam are not expressed when the bacteria are
kept at 32°C. By shifting the bacteria to 42°C for as little
as 15 min, the genes are rapidly induced to very high lev-
els and homologous recombination is very efficient.
Based on galK selection [28], which we modified by the
Kinetics of the humoral immune responses of rabbits and she p immunized with BoHV-4CMV-IgKE2-14∆TKF gure 5
Kinetics of the humoral immune responses of rabbits 
and sheep immunized with BoHV-4CMV-IgKE2-
14∆TK. Sera collected from rabbits (a) and sheep (b) before 
immunization (time 0) and after immunization (time 1, 2, 3, 4 
and 5) were evaluated for anti-BVD neutralizing antibodies 
by serum neutralization (SN) test. Serum neutralizing anti-
bodies against BVDV are expressed as the reciprocal of the 
highest dilution of the serum that inhibited the development 
of virus-induced CPE in MDBK cells. Virus neutralization 
(VN) titers of 2 (log2) were considered to be positive. In 
both panels, each value represents the mean response of 3 
rabbits (a) (** = P < 0.001, * = P < 0,05) or 4 sheep (b) (** = 
P < 0.001, * = P < 0,05). Each test was repeated 3 times and 
statistical significance was evaluated by Student's t test.Page 7 of 12
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that drastically improved the background in the first tar-
geting step, we successfully introduced the CMV-IgKE2-14
expression cassette into the BoHV-4 genome. For homol-
ogous recombination, we chose the TK gene as a target site
because in other herpesviruses, the TK gene inactivation
results in drastic attenuation in vivo [23,24]. Viral vector-
associated risk is a major concern in viral vector develop-
ment, and attenuation is regarded as a desirable feature of
a viral vector and efforts are directed toward the develop-
ment of highly attenuated strains [37]. However, in the
case of BoHV-4, the virus naturally exhibits limited or no
pathogenicity in both natural and experimental hosts
[8,38,39]. Therefore, further attenuation by disruption of
genes in addition to TK is neither necessary nor desirable.
The resulting recombinant, BoHV-4CMV-IgKE2-14∆TK,
has a 94 bp TK gene deletion, and the remaining TK gene
is interrupted by an CMV-IgKE2-14 expression cassette.
Reconstitution of the recombinant virus generated here
resulted in a recombinant vector in which robust expres-
sion of the BVDV transgene was observed in all infected
cell lines tested and immunization of rabbits and sheep
with BoHV-4CMV-IgKE2-14∆TK resulted in the induction
of neutralizing antibodies against BVDV in the absence of
an adjuvant and after a single injection dose.
The use of viruses as vectors for the delivery of heterolo-
gous antigens needs careful consideration because the
immune system has evolved a sophisticated array of
mechanisms to both detect and eliminate invading
viruses. A viral vector also delivers the antigen directly into
the host cell, which allows for high-level intracellular
expression. Hence, the viral vector acts as an adjuvant and
as a delivery system. An effective viral vector should
present the expressed antigen as an immune target and
should remain in the host long enough to stimulate an
effective response. One of the major concerns about vac-
cine vector development is preexisting antivector immu-
nity in the host organism. In the case of BoHV-4, this
should not be a problem, because BoHV-4does not natu-
rally elicit the production of serum neutralizingantibodies
[23,24].
DNA vaccines, like viral vectored vaccines, are capable of
raising both humoral and cellular responses, but, unlike
live virus vaccines, they are extremely stable and versatile
for manufacture and storage. Themain limitation of DNA-
based vaccines remains their low relativeefficacy, requir-
ing multiple boosts with high doses (up to 500 µg of plas-
mid DNA per injection) to generate responses comparable
to those achieved from an attenuated virus vaccination
[23,24]. BoHV-4 is an attractive potential vaccine vector in
that it establishes persistent infections in its natural
bovine host and in an experimental host like the rabbit
[40,41], suggesting that a BoHV-4 vaccine vector would be
particularly useful for long-lasting expression of the heter-
ologous antigen. Although BoHV-4 has been demon-
strated in many tissues during persistent infection by PCR,
in situ hybridization, or recovery of virus after culture
explants, the accumulated evidence suggests that one site
of persistence in both natural and experimental hosts is
cells of the monocyte/macrophage lineage [6,42]. This is
probably the most attractive feature of BoHV-4 in terms of
vaccine vector development. Since macrophages are both
professional antigen-presenting cells and natural targets
of BoHV-4, the delivered heterologous antigen should be
directly processed and presented to the immune system,
ultimately leading to an amplification of the immune
response after the homing of macrophages persistently
infected with BoHV-4 to lymphoid organs like the spleen
and lymph nodes. Another feature of BoHV-4 that makes
it a potential gene delivery vector is the lack of evidence
for oncogenicity. Other gammaherpesviruses like Epstein-
Barr virus (EBV), herpesvirus saimiri (HVS), human her-
pesvirus 8 (HHV-8), and murine gammaherpesvirus-68
(MHV-68) have been associated with the growth-trans-
forming ability [43-45]. In contrast, no evidence for
growth-transformation by BoHV-4 has been obtained
[26]. Each of the genes associated with transformation by
other gammaherpesviruses is unique to each individual
virus, and homologs are not found in other transforming
gammaherpesviruses or BoHV-4 [26]. Considerable effort
has been directed toward the development of the
alphaherpesvirus HSV-1 as a vector for gene therapy, espe-
cially for the nervous system, because HSV-1 is a human
neurotropic virus [37]. A major disadvantage of HSV-1 is
its cytotoxicity for many cell types, including neurons,
although genetic alterations have been made to reduce its
cytotoxicity [37]. In contrast, we have previously shown
that BoHV-4 is able to infect a wide variety of cell types,
including neural cells and liver cells, without cytotoxicity
[46,47]. These observations suggest that BoHV-4 might
have the potential for use as a gene delivery vector for the
nervous system and liver. Due to the dispensability of
many genes, herpesvirus genomes should be able to
accommodate at least 40 kb of foreign sequence [37]. This
would enable the use of complex regulatory regions,
which, in contrast to the simple CMV enhancer-promoter
system which was used, should confer high-level, tissue-
specific and developmentally stable gene expression.
BoHV-4 has a similar size genome to those of other gam-
maherpesviruses, and it is likely that BoHV-4 could carry
significant amounts of heterologous genetic information.
Like other gammaherpesvirus genomes, the BoHV-4
genome is established in an episomal state in persistently
infected cells [48]. Integration of the BoHV-4 genome into
the host cell genome is therefore not necessary for main-
tenance. Recombinant BoHV-4 could theoretically com-
bine the efficiency of a viral delivery system with that of
an artificial chromosome, thus alleviating the influencePage 8 of 12
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host genome.
In the present study BoHV-4CMV-IgKE2-14∆TK has been
shown to be effective in eliciting the humoral immune
response in rabbits and sheep, without any clinical signs,
suggesting the possibility to use BoHV-4 based vector for
vaccination of animal species different from the natural
bovine host. Although the efficacy of a BoHV-4-vectored
vaccine for BVDV needs to be corroborated by an in vivo
challenge study with a pathogenic BVDV in their natural
host, the results we obtained in the rabbit and sheep are
extremely encouraging.
Methods
Plasmid constructs
Full length gE2 remains cell associated; a plasmid con-
struct, pCMV-IgKE2-14, was made that encodes a secreted
form lacking the putative transmembrane domain of gE2,
with pSecTag2HygroA (Invitrogen) as a backbone, and
containing the cytomegalovirus (CMV) promoter and an
immunoglobulin K light chain (Igk) leader sequence
specifying secretion of heterologous proteins. Total RNA
from BVDV strain NADL-infected Madin-Darby bovine
kidney (MDBK) cells was reverse transcribed using the T-
Primed first-strand kit (Amersham Biosciences). Three
microliters of reverse transcribed RNA were amplified
with a primer pair including an HindIII restriction site in
the 5' end (underlined) (sense primer, 5'-CCC GA AGC
TTG CAC TTG GAT TGC AAA CCT GAA TTC-3') in frame
with the Igk signal peptide of the plasmid backbone and
an XhoI restriction sitein the 3' end (underlined) (anti-
sense, 5'-CCC CGC TC GAG AGT GGA CTC AGC GAA
GTA ATC CCG-3') in frame with a polar non structured
14-amino-acid peptide of the plasmid backbone. In order
to obtain pIgKE2-23, the NheI/XhoI fragment from
pIgKE2-14 was sub-cloned into the NheI/XhoI sites of
pEGFP-C1 depleted of EGFP. This construct possesses an
extra 23aa in the C terminal of gE2, belonging to the multi
cloning site of the vector.
The first targeting vector, pTK-KanaGalK-TK, was gener-
ated by sub-cloning the galactokinase prokaryotic expres-
sion cassette (GalK), along with the kanamycin resistant
expression cassette, into the pINT2 shuttle vector [25].
GalK was excised out from pGalK [28] with BamHI/EcoRI,
blunted end with T4 polymerase (Roche) and ligated with
T4 ligase into pINT2 cut with SmaI and dephosphatated
with Shrimp Alkaline Phosphatase (Roche). A Kanamycin
expression cassette was then cut out with MluI from pMu-
Kana vector [47], blunted end and ligated into pINT2GalK
cut with PstI and blunted end, so that the pTK-KanaGalK-
TK was generated.
The second Targeting Vector, pTK-CMV-IgKE2-14-TK, was
generated by sub-cloning the CMV-IgKE2-14 expression
cassette into pINT2GFP (Donofrio et al., 2002). CMV-
IgKE2-14 was excise out from pIgKE2-14 with SalI and
ligated into pINT2GFP cut with SalI to deplete the CMV-
GFP cassette.
Recombineering and selection
Recombineering was performed as previously described
(Warming et al., 2005) with some modifications. Five
hundreds µl of a 32°C overnight culture of SW102 [28]
containing BAC-BoHV-4 [27], were diluted in 25 ml
Luria-Bertani (LB) medium with or without chloram-
phenicol (SIGMA) selection (12.5 µg/ml) in a 50 ml baf-
fled conical flask and grown at 32°C in a shaking water
bath to an OD600 of 0.6. Then, 10 ml was transferred to
another baffled 50 ml conical flask and heat-shocked at
42°C for exactly 15 min in a shaking water bath. The
remaining culture was left at 32°C as the uninduced con-
trol. After 15 min the two samples, induced and unin-
duced, were briefly cooled in ice/water bath slurry and
then transferred to two 15 ml Falcon tubes and pelleted
using 5000 r.p.m. (eppendorf centrifuge) at 0°C for 5
min. The supernatant was poured off and the pellet was
resuspended in 1 ml ice-cold ddH2O by gently swirling
the tubes in ice/water bath slurry. Subsequently, 9 ml ice-
cold ddH2O was added and the samples pelleted again.
This step was repeated once more, the supernatant was
removed and the pellet (50 µl each) was kept on ice until
electroporated with gel-purified ~4.3 kb fragment (TK-
KanaGalK-TK) obtained by cutting pTK-KanaGalK-TK
with XhoI/EcoRI (ROCHE). An aliquot of 25 µl was used
for each electroporation in a 0.1 cm cuvette at 25 µF, 2.5
kV and 201 Ω. After electroporation, the bacteria were
recovered in 1 ml LB (15 ml Falcon tube) for 1 h in a 32°C
shaking water bath. For the counter selection step (see
below), the bacteria were recovered in 10 ml LB in a 50 ml
baffled conical flask and incubated for 4.5 h in a 32°C
shaking water bath.
After the recovery period, the bacteria were washed twice
in sterile 1× M9 salts (6 g/l Na2HPO4, 3 g/l KH2PO4, 1 g/l
NH4Cl and 0.5 g/l NaCl,) (SIGMA) as follows: 1 ml cul-
ture was pelleted in an eppendorf tube at 13,200 r.p.m. for
15" and the supernatant was removed with a pipette. The
pellet was resuspended in 1 ml of 1× M9salts, and pelleted
again. This washing step was repeated once more. After
the second wash, the supernatant was removed and the
pellet was resuspended in 1 ml of 1× M9 salts before plat-
ing serial dilutions (100 µl each of 1:10, 1:100 and 1:1000
dilutions) on M63 minimal medium plates (agar 15 g/l;
(DIFCO, BD Biosciences), 0.2% D-galactose (SIGMA), 1
mg/l D-biotin (SIGMA), 45 mg/l L-leucine (SIGMA) and
50 mg/l kanamycin (SIGMA)). Washing in M9 salts is nec-
essary to remove any rich media from the bacteria prior toPage 9 of 12
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bated 3–5 days at 32°C. Several selected colonies were
picked up, streaked on McConkey agar indicator plates
(DIFCO, BD Biosciences) containing 50 µg/ml of kan-
amycin and incubated at 32°C for 3 days until red colo-
nies appeared. Red colonies were grown over night in 5 ml
of LB containing 50 µg/ml of kanamycin an BAC-BoHV-4
was purified and analyzed through HindIII restriction
enzyme digestion for TK-KanaGalK-TK fragment targeted
integration into the BoHV-4 TK locus.
SW102 bacteria containing KanaGalK targeted BAC-
BoHV-4 genome were grown, heat induced as described
above and electroporated with a gel purified ~4.2 kb frag-
ment (TK-CMV-IgKE2-14-TK) obtained by cutting pTK-
CMV-IgKE2-14-TK with PvuII/ClaI (ROCHE). For the
counter selection step, the bacteria were recovered in 10
ml LB in a 50 ml baffled conical flask and incubated for
4.5 h in a 32°C shaking water bath. Bacteria serial dilu-
tions were plated on M63 minimal medium plates con-
taining 15 g/l agar, 0.2% glycerol (SIGMA), 1 mg/l D-
biotin,45 mg/l L-leucine, 0.2% 2-deoxy-galactose (DOG,
SSIGMA) and 12.5 µg/ml chloramphenicol. Plates were
incubated 3–5 days at 32 °C. Several selected colonies
were picked up, streaked on McConkey agar indicator
plates (DIFCO, BD Biosciences) containing 12.5 µg/ml of
chloramphenicol and incubated at 32°C for 3 days until
white colonies appeared. White colonies were grown in
duplicate for 5–8 hours in 1 ml of LB containing 50 µg/ml
of kanamycin or LB containing 12.5 µg/ml of chloram-
phenicol. Only those colonies growing on chlorampheni-
col and not on kanamycin were kept and grown over night
in 5 ml of LB containing 12.5 µg/ml of chloramphenicol.
BAC-BoHV-4 was purified and analyze through HindIII
restriction enzyme digestion for pTK-CMV-IgKE2-14-TK
fragment targeted integration. Original detailed protocols
for recombineering can also be found at the recombineer-
ing website [49].
Viruses
Recombinant BoHV-4 (BoHV-4CMV-IgKE2-14∆TK), and
wild type BVDV (strain NADL) were propagated by infect-
ing confluent monolayers of MDBK cells at a multiplicity
of infection (m.o.i.) of 0.5 50% tissue culture infectious
doses (TCID50) per cell and maintained in minimal
essential medium (MEM) (SIGMA) with 2% fetal bovine
serum (FBS) for 2 h. The medium was then removed and
replaced by fresh MEM containing 10% FBS. When
approximately 90% of the cell monolayer exhibited cyto-
pathic effect (CPE) (approximately 72 h post infection),
the virus was prepared by freezing and thawing cells three
times and pelleting the virions through 30% sucrose, as
described previously [46]. Virus pellets were resuspended
in cold MEM without FBS. TCID50 were determined with
MDBK cells by limiting dilution.
Cell cultures
Human rhabdomyosarcoma ((RD-4) ATCC CCL-136),
MDBK (ATCC, CCL-22), bovine embryo kidney ((BEL)
from M. Ferrari Istituto Zooprofilattico, Brescia, Italy),
bovine embryo lung ((BEL) from M. Ferrari Istituto Zoo-
profilattico, Brescia, Italy) and bovine macrophage
((BoMac) from V. van Santen, Auburn University, USA)
cell lines were cultured in Dulbecco's modified essential
medium (DMEM) (SIGMA) containing 10% FBS, 2 mM L-
glutamine, 100 IU/ml penicillin (SIGMA), and 100 µg/ml
streptomycin (SIGMA). Primary bovine endometrial cells,
stromal and epithelial (BEND), were obtained from M.
Sheldon (University of London, UK) and kept in RPMI-
1640 (SIGMA) containing 10% FBS, 50 IU/ml of penicil-
lin, 50 µg/ml of streptomycin and 2.5 µg/ml of Amphoter-
icin B.
Cell culture electroporation and recombinant virus 
preparation
MDBK and BEK cells were maintained as a monolayer
with growth medium containing 90% DMEM, 10% FBS,
2 mM L-glutamine, 100 IU/ml penicillin and 10 µg/ml
streptomycin. Cells were sub cultured to a fresh culture
vessel when growth reached 70 to 90% confluence (i.e.,
every 3 to 5 days) and were incubated at 37°C in a humid-
ified atmosphere of 95% air-5% CO2. Plasmid DNA (5
µg) in 500 µl DMEM without serum was electroporated
(Equibio apparatus, 270 V, 960 µF, 4-mm gap cuvettes)
into BEK cells from a confluent 25-cm2 flask. Electropo-
rated cells were returned to the flask, fed the next day, and
split 1:2 when they reached confluence at 2 days post elec-
troporation. Cells were left to grow until CPE appeared.
Recombinant viruses were propagated by infecting conflu-
ent monolayers of MDBK cells at an m.o.i. of 0.5 TCID50
per cell and maintaining them in MEM with 10% FBS for
2 h. The medium was then removed and replaced by fresh
MEM containing 10% FBS. When approximately 90% of
the cell monolayer exhibited CPE (approximately 72 h
post infection), the virus was prepared by freezing and
thawing cells three times and pelleting virions through
30% sucrose, as previously described [46]. Virus pellets
were resuspended in cold MEM without FBS. TCID50
were determined on MDBK cells by limiting dilution.
Bovine macrophage cell line persistently infected with 
BoHV-4CMV-IgKE2-14∆TK (BoMac/BoHV-4CMV-IgKE2-
14∆TK)
BoMac/BoHV-4CMV-IgKE2-14∆TK cells were established
as previously described [50] by infecting BoMac cells, a
cell line established from peritoneal macrophages by
transformation with simian virus 40 DNA [51]. Confluent
monolayers of BoMac cells were inoculated at an m.o.i. of
1 TCID50 per cell with recombinant BoHV-4CMV-IgKE2-
14∆TK. By the third day after inoculation, more than 95%
of cells had detached from the monolayer, leaving behindPage 10 of 12
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ent monolayers established from survivingcells showed
100% infection, as indicated by the strong fluorescentsig-
nal, but without apparent signs of CPE. Also consistent
with our previous observations [50], the persistently
infected macrophages produced infectious BoHV-4CMV-
IgKE2-14∆TK and secreted gE2 (in results). BoMac/BoHV-
4CMV-IgKE2-14∆TK cells were sub cultured at a dilution
of 1:2 every 3 days.
Western immunoblotting
Cell extracts containing 50 µg of total protein were elec-
trophoresed through 12% SDS-polyacrylamide gels and
transferred to nylon membranes by electro blotting. Mem-
branes were incubated with monoclonal anti-BVDV-gE2
antibody (clone 157; VRMD, Inc., Pullman, WA), probed
with horseradish peroxidase-labeled anti-mouse immu-
noglobulin antibody (SIGMA), and visualized by
enhanced chemiluminescence (ECL Kit; PIERCE, Rock-
ford, IL).
Serological tests
Serum neutralization tests were performed as follows.
Twenty five microliters of each serum sample was added
to the first line of wells of 96-well plates. Twenty-five
microliters of DMEM were added to each well and, for
each serum tested, serial twofold dilutions were made.
Positive and negative serum controls were included.
Twenty-five microliters of virus suspension containing
100 TCID50 of BVDV were added to each well. After 1 h
of incubation at 37°C, 50 µl of a MDBK cell suspension
was added to each well and the plates were incubated for
3 days at 37°C. Expression of viral infectivity and serum
neutralizing activity through CPE were detected by micro-
scopy and or by crystal violet staining of the cell monol-
ayer. The neutralization antibody titers were expressed as
the reciprocal of the final dilution of serum that com-
pletely inhibited viral infectivity.
Animal handling and care
Rabbits and sheep were cared for and used in accordance
with Italian laws for animal experimentation. Rabbits and
sheep were maintained at 24°C with a controlled light
cycle (12 h of light, starting at 6:00 a.m.) and with food
and water ad libitum. Blood samples were obtained and
viral injections were performed via the auricular vein for
the rabbits and via jugular vein for the sheep at scheduled
intervals.
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